Assay Blocking Blog calprotectin elisa camp elisa corticosterone elisa Elisa hama antibodies hmgb1 elisa iron assay Isotype mobp antibody Monoclonal p24 elisa pge2 elisa plc gamma 2 protein carbonyl assay protein carbonyls Recombinant Serum tbars assay kit tdgf1 triglyceride assay upp1 Vector
Thyroid diseases and second to fourth digit ratio in Polish adults
The affiliation between second to fourth finger ratio and thyroid ailments is unexplained. There’s a attainable interplay between prenatal exposition to intercourse hormone and thyroid capabilities within the maturity. The research included 175 adults investigated in Łódź within the central Poland.
It consisted of two foremost components: a survey together with questions on prevalence of thyroid gland dysfunction and anthropometric measurements (physique mass and top and size of the second and fourth finger, waist and hip circumferences).
The ladies who had thyroid illness had larger 2D:4D digit ratio (left hand) (imply = 1.004; SD = 0.036) than wholesome ones (imply = 0.989; SD = 0.030) (t = – 2105; p = 0.038; d = 0.707). The affiliation between thyroid ailments prevalence and prenatal steroid hormone exposition is observed. Solely females who had thyroid ailments are likely to have larger 2D:4D digit ratio, for left hand.
Outcomes of feminine and male sufferers affected by coronary artery illness: A nation-wide registry of sufferers admitted as emergency
Presentation and mortality of coronary artery illness (CAD) considerably differs in each sexes. Many of the current knowledge analyzing intercourse variations is older than 10 years and largely was retrieved in scientific trials, that are doubtlessly structured with a bias towards the inclusion of ladies, resulting in a possible selection-bias. In the meantime, with higher diagnostic and therapeutic choices, precise knowledge analyzing intercourse variations in emergency CAD sufferers is uncommon.
Knowledge on all emergency case numbers with CAD analysis in Germany 2017 was retrieved from the German Institute for Medical Documentation and Info. DRG, OPS, and ICD codes had been used to find out comorbidities, in-hospital course, and final result.
Competing threat regression evaluation for in-hospital mortality was carried out analyzing age, European System for Cardiac Operative Danger Analysis (EuroSCORE), severity of CAD, scientific presentation kind and intercourse.264,742 sufferers had been included. Feminine sufferers had been older and had extra comorbidities.
Three-vessel CAD was considerably much less current in feminine sufferers (36.5% vs 47.5%; P < .001). After adjusting for age, EuroSCORE and severity of CAD, feminine intercourse was an impartial predictor of decrease in-hospital mortality (subdistribution hazard ratio [sHR] 0.94, 95% CI: 0.90-0.98, P = .002) in the entire cohort and in non-ST-segment elevation myocardial infarction (NSTEMI) sufferers (sHR 0.85, 95% CI: 0.79-0.92, P < .001), whereas in ST-segment elevation myocardial infarction (STEMI) sufferers, feminine intercourse was related to the next in-hospital mortality (sHR 1.07, 95% CI: 1.01-1.14, P = .029).In all sufferers admitted as emergency with CAD analysis and in all NSTEMI sufferers, feminine intercourse is protecting, whereas in STEMI sufferers, females present the next in-hospital mortality threat.
TIPIC-A Newly Acknowledged Syndrome: Multimodality Imaging of a Uncommon Clinicoradiological Entity
Carotidynia is a controversial clinicopathological entity vastly described in Western literature as neck ache within the area of carotid bifurcation secondary to an underlying inflammatory etiology. Radiologically, this seems as perivascular irritation and has lately been designated as transient perivascular irritation of the carotid artery (TIPIC) syndrome.
The authors of this report focus on the multimodality imaging options of a uncommon case of this illness in our nation to familiarize radiologists with the imaging findings and to encourage the inclusion of TIPIC syndrome as a differential analysis for focal neck ache.
Neonatal opioid withdrawal syndrome: a evaluate of the science and a glance towards the usage of buprenorphine for affected infants
Neonates born to moms taking opioids throughout being pregnant are in danger for neonatal opioid withdrawal syndrome (NOWS), for which there isn’t a acknowledged normal method to care. Nonpharmacologic therapy is usually used as a first-line method for administration, and pharmacologic therapy is added when scientific indicators will not be responding to nonpharmacologic measures alone.
Though morphine and methadone are essentially the most generally used pharmacotherapies for NOWS, buprenorphine has emerged as a therapy possibility primarily based on its pharmacologic profile and outcomes from preliminary single web site scientific trials.
The target of this report is to offer an summary of NOWS together with a abstract of ongoing work within the discipline and to evaluate the state of the science, information gaps, and sensible concerns particular to the usage of buprenorphine for the therapy of NOWS as mentioned by a panel of specialists throughout a digital workshop hosted by the Nationwide Institutes of Well being.
Dizziness in Parkinson’s illness sufferers is related to vestibular operate
Dizziness is widespread in Parkinson’s illness (PD) sufferers. It’s recognized that orthostatic hypotension (OH) is the principle reason behind such dizziness, however even with out OH, fairly just a few PD sufferers complain of dizziness within the clinic. It may be considered non-specific as a result of most of those sufferers don’t have any neurological abnormalities.
We hypothesized that any such dizziness could be related to vestibular operate, though included sufferers didn’t have clinically confirmed vestibulopathy. We studied 84 sufferers with out OH amongst 121 PD sufferers. Their scientific options and performance had been in contrast between sufferers with and with out dizziness.
Hoehn and Yahr stage (H&Y stage), the Unified Parkinson’s Illness Score Scale (UPDRS) half III, the Korean model of the Mini-Psychological State Examination (Okay-MMSE), schooling years, illness period, whole levodopa equal day by day dose (LEDD), the presence of dizziness, the dizziness severity, and orthostatic hypotension had been examined.
Vestibular evoked myogenic potentials (VEMPs) had been used to characterize vestibular operate. Ocular (oVEMPs) and cervical (cVEMPs) had been recorded. oVEMPs in the fitting aspect confirmed considerably lowered potentials (p = 0.016) in PD sufferers with dizziness, however cVEMPs didn’t (all ps > 0.2). Bilateral absent oVEMP responses had been extra widespread in PD sufferers with dizziness (p = 0.022), however the frequencies of bilateral absent cVEMP responses weren’t completely different between the dizzy and non-dizzy teams (p = 0.898).
Bleomycin Sulfate |
|||
| A8331-5.1 | ApexBio | 10 mM (in 1mL DMSO) | EUR 200 |
|
Description: DNA Damage/DNA Repair|DNA Synthesis |
|||
Bleomycin Sulfate |
|||
| A8331-50 | ApexBio | 50 mg | EUR 375.2 |
|
Description: DNA Damage/DNA Repair|DNA Synthesis |
|||
Bleomycin Sulfate |
|||
| A8331-S | ApexBio | Evaluation Sample | EUR 24 |
|
Description: DNA Damage/DNA Repair|DNA Synthesis |
|||
Bleomycin Sulfate |
|||
| 40210016-1 | Bio-WORLD | 5 mg | EUR 199.15 |
Bleomycin Sulfate |
|||
| 40210016-2 | Bio-WORLD | 15 mg | EUR 293.43 |
Bleomycin Sulfate |
|||
| 40210016-3 | Bio-WORLD | 25 mg | EUR 499.64 |
Bleomycin Sulfate |
|||
| 40210016-4 | Bio-WORLD | 50 mg | EUR 941.52 |
Bleomycin sulfate |
|||
| 2246-10 | Biovision | each | EUR 366 |
Bleomycin sulfate |
|||
| 2246-50 | Biovision | each | EUR 1227.6 |
Bleomycin sulfate |
|||
| 100090 | MedKoo Biosciences | 5.0mg | EUR 150 |
Bleomycin sulfate |
|||
| abx282729-100g | Abbexa | 100 µg | Ask for price |
Bleomycin sulfate |
|||
| abx282729-20g | Abbexa | 20 µg | EUR 143.75 |
Bleomycin sulfate |
|||
| abx282729-50g | Abbexa | 50 µg | EUR 350 |
Bleomycin sulfate |
|||
| GA7621 | Glentham Life Sciences | 5mg | EUR 130.36 |
Bleomycin sulfate |
|||
| GA7621-10 | Glentham Life Sciences | 10 | EUR 71.1 |
Bleomycin sulfate |
|||
| GA7621-10MG | Glentham Life Sciences | 10 mg | EUR 122.4 |
Bleomycin sulfate |
|||
| GA7621-25 | Glentham Life Sciences | 25 | EUR 142.4 |
Bleomycin sulfate |
|||
| GA7621-25MG | Glentham Life Sciences | 25 mg | EUR 208.8 |
Bleomycin sulfate |
|||
| GA7621-5 | Glentham Life Sciences | 5 | EUR 43.5 |
Bleomycin sulfate |
|||
| GA7621-5MG | Glentham Life Sciences | 5 mg | EUR 88.8 |
Bleomycin (sulfate) |
|||
| HY-17565 | MedChemExpress | 50mg | EUR 727.28 |
|
Description: Bleomycin sulfate is a DNA synthesis inhibitor. Bleomycin hydrochloride is a DNA damaging agent. Bleomycin sulfate is an antitumor antibiotic[1]. |
|||
Bleomycin Sulfate |
|||
| MBS578685-10mg | MyBiosource | 10mg | EUR 195 |
Bleomycin Sulfate |
|||
| MBS578685-25mg | MyBiosource | 25mg | EUR 310 |
Bleomycin Sulfate |
|||
| MBS578685-2mg | MyBiosource | 2mg | EUR 145 |
Bleomycin Sulfate |
|||
| MBS578685-50mg | MyBiosource | 50mg | EUR 470 |
Bleomycin Sulfate |
|||
| MBS578685-5mg | MyBiosource | 5mg | EUR 160 |
Bleomycin sulfate |
|||
| MBS384372-100mg | MyBiosource | 100mg | EUR 960 |
Bleomycin sulfate |
|||
| MBS384372-10mg | MyBiosource | 10mg | EUR 190 |
Bleomycin sulfate |
|||
| MBS384372-1mLinDMSO | MyBiosource | 1mL(inDMSO) | EUR 300 |
Bleomycin sulfate |
|||
| MBS384372-25mg | MyBiosource | 25mg | EUR 310 |
Bleomycin sulfate |
|||
| MBS384372-50mg | MyBiosource | 50mg | EUR 545 |
Bleomycin sulfate |
|||
| MBS3606495-10mg | MyBiosource | 10mg | EUR 260 |
Bleomycin sulfate |
|||
| MBS3606495-25mg | MyBiosource | 25mg | EUR 375 |
Bleomycin sulfate |
|||
| MBS3606495-2mg | MyBiosource | 2mg | EUR 200 |
Bleomycin sulfate |
|||
| MBS3606495-50mg | MyBiosource | 50mg | EUR 530 |
Bleomycin sulfate |
|||
| MBS3606495-5mg | MyBiosource | 5mg | EUR 225 |
Bleomycin Sulfate |
|||
| T6116-10mg | TargetMol Chemicals | 10mg | Ask for price |
|
Description: Bleomycin Sulfate |
|||
Bleomycin Sulfate |
|||
| T6116-1g | TargetMol Chemicals | 1g | Ask for price |
|
Description: Bleomycin Sulfate |
|||
Bleomycin Sulfate |
|||
| T6116-1mg | TargetMol Chemicals | 1mg | Ask for price |
|
Description: Bleomycin Sulfate |
|||
Bleomycin Sulfate |
|||
| T6116-50mg | TargetMol Chemicals | 50mg | Ask for price |
|
Description: Bleomycin Sulfate |
|||
Bleomycin Sulfate |
|||
| T6116-5mg | TargetMol Chemicals | 5mg | Ask for price |
|
Description: Bleomycin Sulfate |
|||
Bleomycin Sulfate (A mixture of bleomycin sulfate salts) TFA Salt >90% |
|||
| B595830 | Toronto Research Chemicals | 10mg | EUR 115 |
Bleomycin Sulfate (A mixture of bleomycin sulfate salts) (>90%) (DISCONTINUED) |
|||
| B595800 | Toronto Research Chemicals | 10mg | EUR 115 |
|
Description: 9041-93-4 |
|||
Bleomycin sulfate USP |
|||
| B005-10MG | TOKU-E | 10 mg | EUR 89.69 |
|
Description: 9041-93-4 |
|||
Bleomycin sulfate USP |
|||
| B005-50MG | TOKU-E | 50 mg | EUR 268.39 |
|
Description: 9041-93-4 |
|||
Bleomycin A2 sulfate EvoPure® |
|||
| B019-10MG | TOKU-E | 10 mg | EUR 479.46 |
|
Description: 11116-31-7 (Bleomycin A2 base) |
|||
Bleomycin complex (as sulfate salts) (Blenoxane, Bleo, Blexane) |
|||
| MBS651329-10mg | MyBiosource | 10mg | EUR 505 |
Bleomycin complex (as sulfate salts) (Blenoxane, Bleo, Blexane) |
|||
| MBS651329-5x10mg | MyBiosource | 5x10mg | EUR 2130 |
BLMH (Bleomycin Hydrolase, BH, BLM Hydrolase, BMH) (Biotin) |
|||
| MBS6140830-01mL | MyBiosource | 0.1(mL | EUR 875 |
BLMH (Bleomycin Hydrolase, BH, BLM Hydrolase, BMH) (Biotin) |
|||
| MBS6140830-5x01mL | MyBiosource | 5x0.1mL | EUR 3800 |
BLMH (Bleomycin Hydrolase, BH, BLM Hydrolase, BMH) |
|||
| MBS644087-005mg | MyBiosource | 0.05mg | EUR 630 |
BLMH (Bleomycin Hydrolase, BH, BLM Hydrolase, BMH) |
|||
| MBS644087-5x005mg | MyBiosource | 5x0.05mg | EUR 2680 |
BLMH (Bleomycin Hydrolase, BH, BLM Hydrolase, BMH) |
|||
| MBS6009609-01mg | MyBiosource | 0.1(mg | EUR 630 |
BLMH (Bleomycin Hydrolase, BH, BLM Hydrolase, BMH) |
|||
| MBS6009609-5x01mg | MyBiosource | 5x0.1mg | EUR 2680 |
BLMH (Bleomycin Hydrolase, BH, BLM Hydrolase, BMH) (PE) |
|||
| MBS6156739-01mL | MyBiosource | 0.1(mL | EUR 875 |
BLMH (Bleomycin Hydrolase, BH, BLM Hydrolase, BMH) (PE) |
|||
| MBS6156739-5x01mL | MyBiosource | 5x0.1mL | EUR 3800 |
BLMH (Bleomycin Hydrolase, BH, BLM Hydrolase, BMH) (AP) |
|||
| MBS6130224-01mL | MyBiosource | 0.1(mL | EUR 875 |
BLMH (Bleomycin Hydrolase, BH, BLM Hydrolase, BMH) (AP) |
|||
| MBS6130224-5x01mL | MyBiosource | 5x0.1mL | EUR 3800 |
BLMH (Bleomycin Hydrolase, BH, BLM Hydrolase, BMH) APC |
|||
| MBS6135527-01mL | MyBiosource | 0.1(mL | EUR 875 |
BLMH (Bleomycin Hydrolase, BH, BLM Hydrolase, BMH) APC |
|||
| MBS6135527-5x01mL | MyBiosource | 5x0.1mL | EUR 3800 |
BLMH (Bleomycin Hydrolase, BH, BLM Hydrolase, BMH) (HRP) |
|||
| MBS6151436-01mL | MyBiosource | 0.1(mL | EUR 875 |
BLMH (Bleomycin Hydrolase, BH, BLM Hydrolase, BMH) (HRP) |
|||
| MBS6151436-5x01mL | MyBiosource | 5x0.1mL | EUR 3800 |
BLMH (Bleomycin Hydrolase, BH, BLM Hydrolase, BMH) (FITC) |
|||
| MBS6146133-01mL | MyBiosource | 0.1(mL | EUR 875 |
BLMH (Bleomycin Hydrolase, BH, BLM Hydrolase, BMH) (FITC) |
|||
| MBS6146133-5x01mL | MyBiosource | 5x0.1mL | EUR 3800 |
CLIA Kit for Bleomycin Hydrolase (BLMH) |
|||
| SCC220Hu | Cloud-Clone | 96Т | EUR 840 |
ELISA Kit for Bleomycin Hydrolase (BLMH) |
|||
| SEC220Hu | Cloud-Clone | 96Т | EUR 700 |
BLMH (Bleomycin Hydrolase, BH, BLM Hydrolase, BMH) (MaxLight 650) |
|||
| MBS6221112-01mL | MyBiosource | 0.1(mL | EUR 875 |
BLMH (Bleomycin Hydrolase, BH, BLM Hydrolase, BMH) (MaxLight 650) |
|||
| MBS6221112-5x01mL | MyBiosource | 5x0.1mL | EUR 3800 |
BLMH (Bleomycin Hydrolase, BH, BLM Hydrolase, BMH) (MaxLight 490) |
|||
| MBS6199762-01mL | MyBiosource | 0.1(mL | EUR 875 |
BLMH (Bleomycin Hydrolase, BH, BLM Hydrolase, BMH) (MaxLight 490) |
|||
| MBS6199762-5x01mL | MyBiosource | 5x0.1mL | EUR 3800 |
BLMH (Bleomycin Hydrolase, BH, BLM Hydrolase, BMH) (MaxLight 550) |
|||
| MBS6210437-01mL | MyBiosource | 0.1(mL | EUR 875 |
BLMH (Bleomycin Hydrolase, BH, BLM Hydrolase, BMH) (MaxLight 550) |
|||
| MBS6210437-5x01mL | MyBiosource | 5x0.1mL | EUR 3800 |
BLMH (Bleomycin Hydrolase, BH, BLM Hydrolase, BMH) (MaxLight 405) |
|||
| MBS6189087-01mL | MyBiosource | 0.1(mL | EUR 875 |
BLMH (Bleomycin Hydrolase, BH, BLM Hydrolase, BMH) (MaxLight 405) |
|||
| MBS6189087-5x01mL | MyBiosource | 5x0.1mL | EUR 3800 |
BLMH (Bleomycin Hydrolase, BH, BLM Hydrolase, BMH) (MaxLight 750) |
|||
| MBS6231787-01mL | MyBiosource | 0.1(mL | EUR 875 |
BLMH (Bleomycin Hydrolase, BH, BLM Hydrolase, BMH) (MaxLight 750) |
|||
| MBS6231787-5x01mL | MyBiosource | 5x0.1mL | EUR 3800 |
Bleomycin Hydrolase, Recombinant, Human (BH, BLMH, BMH, BLM Hydrolase) |
|||
| MBS636820-001mg | MyBiosource | 0.01mg | EUR 885 |
Bleomycin Hydrolase, Recombinant, Human (BH, BLMH, BMH, BLM Hydrolase) |
|||
| MBS636820-5x001mg | MyBiosource | 5x0.01mg | EUR 3765 |
ELISA kit for Human BLMH (Bleomycin Hydrolase) |
|||
| ELK3153 | ELK Biotech | 1 plate of 96 wells | EUR 518.4 |
|
Description: A sandwich ELISA kit for detection of Bleomycin Hydrolase from Human in samples from blood, serum, plasma, cell culture fluid and other biological fluids. |
|||
Bleomycin |
|||
| B053-10MG | TOKU-E | 10 mg | EUR 150 |
|
Description: 11056-06-7 |
|||
Bleomycin |
|||
| B053-50MG | TOKU-E | 50 mg | EUR 524.55 |
|
Description: 11056-06-7 |
|||
Bleomycin |
|||
| HY-108345 | MedChemExpress | Get quote | Ask for price |
|
Description: Bleomycin is a glycopeptide antibiotic. Bleomycin has potent antitumour activities against a range of lymphomas, head and neck cancers and germ-cell tumours. Bleomycin can be used for the research of cancer and chemotherapy[1][2][3][4]. |
|||
Bleomycin |
|||
| MBS3840330-10mg | MyBiosource | 10mg | EUR 430 |
Bleomycin |
|||
| MBS3840330-5mg | MyBiosource | 5mg | EUR 270 |
Bleomycin |
|||
| MBS3840330-5x10mg | MyBiosource | 5x10mg | EUR 1920 |
Bleomycin Hydrolase (BLMH, BH, BMH) (Biotin) |
|||
| MBS6445251-01mL | MyBiosource | 0.1mL | EUR 950 |
Bleomycin Hydrolase (BLMH, BH, BMH) (Biotin) |
|||
| MBS6445251-5x01mL | MyBiosource | 5x0.1mL | EUR 4120 |
Bleomycin Hydrolase (BLMH) Antibody (Biotin) |
|||
| 20-abx272261 | Abbexa |
|
|
Bleomycin Hydrolase (BLMH) Antibody (Biotin) |
|||
| abx272261-1ml | Abbexa | 1 ml | EUR 825 |
Bleomycin Hydrolase (BLMH) Antibody (Biotin) |
|||
| abx272261-200l | Abbexa | 200 µl | EUR 362.5 |
Bleomycin Hydrolase (BLMH) Antibody (Biotin) |
|||
| 20-abx273337 | Abbexa |
|
|
Bleomycin Hydrolase (BLMH) Antibody (Biotin) |
|||
| abx273337-1g | Abbexa | 1 g | EUR 387.5 |
Bleomycin Hydrolase (BH, BLMH, BMH) |
|||
| MBS601898-01mg | MyBiosource | 0.1mg | EUR 680 |
Bleomycin Hydrolase (BH, BLMH, BMH) |
|||
| MBS601898-5x01mg | MyBiosource | 5x0.1mg | EUR 2910 |
Bleomycin Hydrolase (BLMH) Antibody |
|||
| abx005014-100l | Abbexa | 100 µl | EUR 400 |
Bleomycin Hydrolase (BLMH) Antibody |
|||
| 20-abx005014 | Abbexa |
|
|
Bleomycin Hydrolase (BLMH) Antibody |
|||
| abx005014-20l | Abbexa | 20 µl | EUR 175 |
Bleomycin Hydrolase (BLMH) Antibody |
|||
| abx005014-50l | Abbexa | 50 µl | EUR 275 |
Bleomycin Hydrolase (BLMH) Antibody |
|||
| abx034944-100g | Abbexa | 100 µg | EUR 281.25 |
Bleomycin Hydrolase (BLMH) Antibody |
|||
| abx034944-400ul | Abbexa | 400 ul | EUR 627.6 |
Bleomycin Hydrolase (BLMH) Antibody |
|||
| abx034944-80l | Abbexa | 80 µl | EUR 343.2 |
Bleomycin Hydrolase (BLMH) Antibody |
|||
| abx111231-100l | Abbexa | 100 µl | EUR 612.5 |
Bleomycin Hydrolase (BLMH) Antibody |
|||
| 20-abx111231 | Abbexa |
|
|
Bleomycin Hydrolase (BLMH) Antibody |
|||
| abx101837-100l | Abbexa | 100 µl | EUR 275 |
Bleomycin Hydrolase (BLMH) Antibody |
|||
| 20-abx101837 | Abbexa |
|
|
Bleomycin Hydrolase (BLMH) Antibody |
|||
| abx101837-1ml | Abbexa | 1 ml | EUR 750 |
Bleomycin Hydrolase (BLMH) Antibody |
|||
| abx101837-200l | Abbexa | 200 µl | EUR 337.5 |
Bleomycin Hydrolase (BLMH) Antibody |
|||
| abx101838-100l | Abbexa | 100 µl | EUR 275 |
Bleomycin Hydrolase (BLMH) Antibody |
|||
| 20-abx101838 | Abbexa |
|
|
Bleomycin Hydrolase (BLMH) Antibody |
|||
| abx101838-1ml | Abbexa | 1 ml | EUR 775 |
Bleomycin Hydrolase (BLMH) Antibody |
|||
| abx101838-200l | Abbexa | 200 µl | EUR 350 |
Bleomycin Hydrolase (BLMH) Antibody |
|||
| abx101839-100l | Abbexa | 100 µl | EUR 287.5 |
Bleomycin Hydrolase (BLMH) Antibody |
|||
| 20-abx101839 | Abbexa |
|
|
Bleomycin Hydrolase (BLMH) Antibody |
|||
| abx101839-1ml | Abbexa | 1 ml | EUR 812.5 |
Bleomycin Hydrolase (BLMH) Antibody |
|||
| abx101839-200l | Abbexa | 200 µl | EUR 362.5 |
Bleomycin Hydrolase (BLMH) Antibody |
|||
| abx101840-100l | Abbexa | 100 µl | EUR 287.5 |
Bleomycin Hydrolase (BLMH) Antibody |
|||
| 20-abx101840 | Abbexa |
|
|
Bleomycin Hydrolase (BLMH) Antibody |
|||
| abx101840-1ml | Abbexa | 1 ml | EUR 812.5 |
Bleomycin Hydrolase (BLMH) Antibody |
|||
| abx101840-200l | Abbexa | 200 µl | EUR 362.5 |
Bleomycin Hydrolase (BLMH) Antibody |
|||
| 20-abx171422 | Abbexa |
|
|
Bleomycin Hydrolase (BLMH) Antibody |
|||
| abx171422-1ml | Abbexa | 1 ml | EUR 787.5 |
Bleomycin Hydrolase (BLMH) Antibody |
|||
| abx320093-100l | Abbexa | 100 µl | EUR 350 |
Bleomycin Hydrolase (BLMH) Antibody |
|||
| 20-abx320093 | Abbexa |
|
|
Bleomycin Hydrolase (BLMH) Antibody |
|||
| abx320093-50l | Abbexa | 50 µl | EUR 237.5 |
Bleomycin Hydrolase (BLMH) Antibody |
|||
| abx321698-100g | Abbexa | 100 µg | EUR 350 |
Bleomycin Hydrolase (BLMH) Antibody |
|||
| 20-abx321698 | Abbexa |
|
|
Bleomycin Hydrolase (BLMH) Antibody |
|||
| abx321698-50g | Abbexa | 50 µg | EUR 237.5 |
Bleomycin Hydrolase (BLMH) Antibody |
|||
| abx230907-100g | Abbexa | 100 µg | EUR 350 |
Bleomycin Hydrolase (BLMH) Antibody |
|||
| abx230907-100ug | Abbexa | 100 ug | EUR 577.2 |
bleomycin hydrolase (BLMH), Antibody |
|||
| GWB-E38D5A | GenWay Biotech | 1 ml | Ask for price |
Bleomycin B2 |
|||
| B595820 | Toronto Research Chemicals | 0.5mg | EUR 2685 |
|
Description: 9060-10-0 |
|||
Bleomycin A2 |
|||
| HY-146646 | MedChemExpress | Get quote | Ask for price |
|
Description: Bleomycin A2, an antitumor antibiotic promoting DNA-degradation, is an aspartate/asparagine-β-hydroxylase (AspH) inhibitor with an IC50 of 1.47 μM[1]. |
|||
3`UTR clone of bleomycin hydrolase (BLMH) for miRNA target validation |
|||
| SC210098 | Origene Technologies GmbH | 10 µg | Ask for price |
Recombinant Bleomycin Hydrolase (BLMH) |
|||
| MBS2012402-001mg | MyBiosource | 0.01mg | EUR 135 |
Recombinant Bleomycin Hydrolase (BLMH) |
|||
| MBS2012402-005mg | MyBiosource | 0.05mg | EUR 215 |
Recombinant Bleomycin Hydrolase (BLMH) |
|||
| MBS2012402-01mg | MyBiosource | 0.1mg | EUR 295 |
Recombinant Bleomycin Hydrolase (BLMH) |
|||
| MBS2012402-02mg | MyBiosource | 0.2mg | EUR 355 |
Recombinant Bleomycin Hydrolase (BLMH) |
|||
| MBS2012402-05mg | MyBiosource | 0.5mg | EUR 650 |
Recombinant Bleomycin Hydrolase (BLMH) |
|||
| MBS2010553-001mg | MyBiosource | 0.01mg | EUR 160 |
Recombinant Bleomycin Hydrolase (BLMH) |
|||
| MBS2010553-005mg | MyBiosource | 0.05mg | EUR 280 |
Recombinant Bleomycin Hydrolase (BLMH) |
|||
| MBS2010553-01mg | MyBiosource | 0.1mg | EUR 405 |
Recombinant Bleomycin Hydrolase (BLMH) |
|||
| MBS2010553-02mg | MyBiosource | 0.2mg | EUR 490 |
Recombinant Bleomycin Hydrolase (BLMH) |
|||
| MBS2010553-05mg | MyBiosource | 0.5mg | EUR 930 |
Recombinant Bleomycin Hydrolase (BLMH) |
|||
| MBS2018341-001mg | MyBiosource | 0.01mg | EUR 165 |
Recombinant Bleomycin Hydrolase (BLMH) |
|||
| MBS2018341-005mg | MyBiosource | 0.05mg | EUR 290 |
Recombinant Bleomycin Hydrolase (BLMH) |
|||
| MBS2018341-01mg | MyBiosource | 0.1mg | EUR 435 |
Recombinant Bleomycin Hydrolase (BLMH) |
|||
| MBS2018341-02mg | MyBiosource | 0.2mg | EUR 525 |
Recombinant Bleomycin Hydrolase (BLMH) |
|||
| MBS2018341-05mg | MyBiosource | 0.5mg | EUR 1005 |
Recombinant Bleomycin Hydrolase (BLMH) |
|||
| RPU40468-100ug | Biomatik Corporation | 100ug | EUR 468.6 |
Recombinant Bleomycin Hydrolase (BLMH) |
|||
| RPU40468-1mg | Biomatik Corporation | 1mg | EUR 2074.8 |
Recombinant Bleomycin Hydrolase (BLMH) |
|||
| RPU40468-50ug | Biomatik Corporation | 50ug | EUR 376.2 |
Recombinant Bleomycin Hydrolase (BLMH) |
|||
| RPU40469-100ug | Biomatik Corporation | 100ug | EUR 411.4 |
Recombinant Bleomycin Hydrolase (BLMH) |
|||
| RPU40469-1mg | Biomatik Corporation | 1mg | EUR 1622.4 |
Recombinant Bleomycin Hydrolase (BLMH) |
|||
| RPU40469-50ug | Biomatik Corporation | 50ug | EUR 249.6 |
Recombinant Bleomycin Hydrolase (BLMH) |
|||
| RPU40470-100ug | Biomatik Corporation | 100ug | EUR 504.9 |
Recombinant Bleomycin Hydrolase (BLMH) |
|||
| RPU40470-1mg | Biomatik Corporation | 1mg | EUR 2238.6 |
Recombinant Bleomycin Hydrolase (BLMH) |
|||
| RPU40470-50ug | Biomatik Corporation | 50ug | EUR 405.9 |
Recombinant Bleomycin Hydrolase (BLMH) |
|||
| RPC220Hu01 | Cloud-Clone | 10ug | EUR 152 |
Recombinant Bleomycin Hydrolase (BLMH) |
|||
| 4-RPC220Hu01 | Cloud-Clone |
|
|
|
Description: Recombinant Human Bleomycin Hydrolase expressed in: E.coli |
|||
Recombinant Bleomycin Hydrolase (BLMH) |
|||
| RPC220Mu01 | Cloud-Clone | 10ug | EUR 164 |
Recombinant Bleomycin Hydrolase (BLMH) |
|||
| 4-RPC220Mu01 | Cloud-Clone |
|
|
|
Description: Recombinant Mouse Bleomycin Hydrolase expressed in: E.coli |
|||
Recombinant Bleomycin Hydrolase (BLMH) |
|||
| RPC220Ra01 | Cloud-Clone | 10ug | EUR 104 |
Recombinant Bleomycin Hydrolase (BLMH) |
|||
| 4-RPC220Ra01 | Cloud-Clone |
|
|
|
Description: Recombinant Rat Bleomycin Hydrolase expressed in: E.coli |
|||
Bleomycin Acid |
|||
| B595810 | Toronto Research Chemicals | 5mg | EUR 3000 |
|
Description: 37364-66-2 |
|||
Bleomycin Hydrolase (BLMH, BH, BMH) (AP) |
|||
| MBS6445249-01mL | MyBiosource | 0.1mL | EUR 950 |
Bleomycin Hydrolase (BLMH, BH, BMH) (AP) |
|||
| MBS6445249-5x01mL | MyBiosource | 5x0.1mL | EUR 4120 |
Bleomycin Hydrolase (BLMH, BH, BMH) (PE) |
|||
| MBS6445259-01mL | MyBiosource | 0.1mL | EUR 950 |
Bleomycin Hydrolase (BLMH, BH, BMH) (PE) |
|||
| MBS6445259-5x01mL | MyBiosource | 5x0.1mL | EUR 4120 |
Bleomycin Hydrolase (BLMH, BH, BMH) (APC) |
|||
| MBS6445250-01mL | MyBiosource | 0.1mL | EUR 950 |
Bleomycin Hydrolase (BLMH, BH, BMH) (APC) |
|||
| MBS6445250-5x01mL | MyBiosource | 5x0.1mL | EUR 4120 |
Bleomycin Hydrolase (BLMH, BH, BMH) (HRP). |
|||
| MBS6445253-01mL | MyBiosource | 0.1mL | EUR 950 |
Bleomycin Hydrolase (BLMH, BH, BMH) (HRP). |
|||
| MBS6445253-5x01mL | MyBiosource | 5x0.1mL | EUR 4120 |
Bleomycin Chloride (A mixture of bleomycin chloride salts) >90% |
|||
| B595805 | Toronto Research Chemicals | 1mg | EUR 64 |
Rat Bleomycin Hydrolase (BLMH) Protein |
|||
| abx065546-100g | Abbexa | 100 µg | EUR 387.5 |
Rat Bleomycin Hydrolase (BLMH) Protein |
|||
| 20-abx065546 | Abbexa |
|
|
Rat Bleomycin Hydrolase (BLMH) Protein |
|||
| abx065546-10g | Abbexa | 10 µg | EUR 175 |
Rat Bleomycin Hydrolase (BLMH) Protein |
|||
| abx065546-50g | Abbexa | 50 µg | EUR 275 |
Bleomycin Hydrolase (BLMH, BH, BMH) (FITC) |
|||
| MBS6445252-01mL | MyBiosource | 0.1mL | EUR 950 |
Bleomycin Hydrolase (BLMH, BH, BMH) (FITC) |
|||
| MBS6445252-5x01mL | MyBiosource | 5x0.1mL | EUR 4120 |
Human Bleomycin Hydrolase (BLMH) Enzyme |
|||
| abx073168-10kDa1g | Abbexa | 10 kDa; 1 g | EUR 325 |
Human Bleomycin Hydrolase (BLMH) Enzyme |
|||
| abx073168-20kDa1g | Abbexa | 20 kDa; 1 g | EUR 225 |
Human Bleomycin Hydrolase (BLMH) Enzyme |
|||
| abx073168-5kDa1g | Abbexa | 5 kDa; 1 g | EUR 3550 |
Human Bleomycin Hydrolase (BLMH) Protein |
|||
| abx065545-100g | Abbexa | 100 µg | Ask for price |
Human Bleomycin Hydrolase (BLMH) Protein |
|||
| 20-abx065545 | Abbexa |
|
|
Human Bleomycin Hydrolase (BLMH) Protein |
|||
| abx065545-10g | Abbexa | 10 µg | EUR 1962.5 |
Human Bleomycin Hydrolase (BLMH) Protein |
|||
| abx065545-50g | Abbexa | 50 µg | EUR 4912.5 |
Mouse Bleomycin Hydrolase (BLMH) Protein |
|||
| abx065547-100g | Abbexa | 100 µg | EUR 537.5 |
Mouse Bleomycin Hydrolase (BLMH) Protein |
|||
| 20-abx065547 | Abbexa |
|
|
Mouse Bleomycin Hydrolase (BLMH) Protein |
|||
| abx065547-10g | Abbexa | 10 µg | EUR 212.5 |
Mouse Bleomycin Hydrolase (BLMH) Protein |
|||
| abx065547-50g | Abbexa | 50 µg | EUR 375 |
Bleomycin Hydrolase (BLMH) Antibody (FITC) |
|||
| 20-abx273637 | Abbexa |
|
|
Bleomycin Hydrolase (BLMH) Antibody (FITC) |
|||
| abx273637-25mg | Abbexa | 25 mg | EUR 1050 |
Bleomycin Hydrolase (BLMH) Antibody (FITC) |
|||
| abx273637-5mg | Abbexa | 5 mg | EUR 437.5 |
Mouse Bleomycin Hydrolase (BLMH) Protein |
|||
| abx693308-10nmol | Abbexa | 10 nmol | Ask for price |
Mouse Bleomycin Hydrolase (BLMH) Protein |
|||
| abx693308-5nmol | Abbexa | 5 nmol | EUR 825 |
Rat Bleomycin hydrolase(BLMH) ELISA kit |
|||
| E01A10616 | BlueGene | 96T | EUR 700 |
|
Description: ELISA |
|||
Pig Bleomycin hydrolase(BLMH) ELISA kit |
|||
| E07B0805-192T | BlueGene | 192 tests | EUR 1524 |
|
Description: A sandwich ELISA for quantitative measurement of Porcine Bleomycin hydrolase(BLMH) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
|||
Pig Bleomycin hydrolase(BLMH) ELISA kit |
|||
| E07B0805-48 | BlueGene | 1 plate of 48 wells | EUR 624 |
|
Description: A sandwich ELISA for quantitative measurement of Porcine Bleomycin hydrolase(BLMH) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
|||
Pig Bleomycin hydrolase(BLMH) ELISA kit |
|||
| E07B0805-96 | BlueGene | 1 plate of 96 wells | EUR 822 |
|
Description: A sandwich ELISA for quantitative measurement of Porcine Bleomycin hydrolase(BLMH) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
|||
Dog Bleomycin hydrolase(BLMH) ELISA kit |
|||
| E08B0805-192T | BlueGene | 192 tests | EUR 1524 |
|
Description: A sandwich ELISA for quantitative measurement of Canine Bleomycin hydrolase(BLMH) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
|||
Dog Bleomycin hydrolase(BLMH) ELISA kit |
|||
| E08B0805-48 | BlueGene | 1 plate of 48 wells | EUR 624 |
|
Description: A sandwich ELISA for quantitative measurement of Canine Bleomycin hydrolase(BLMH) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
|||
Dizziness in PD sufferers with out orthostatic hypotension could also be related to vestibular hypofunction. Our outcomes present proof that may support clinicians when making a therapy plan for sufferers with dizziness. i.e., methods to boost lowered vestibular operate could also be useful, however this suggestion stays to be evaluated.
